HLX10 for MSI-H or dMMR tumors after standard treatment fails
Treatments studied
Part of Cancer clinical trials.
This trial tests HLX10 (given alone) for people with solid tumors that have MSI-H or dMMR—tumor changes linked to how the cancer responds to certain therapies—when standard treatment didn’t work. It aims to see whether HLX10 can slow the cancer and improve outcomes after prior treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be willing to sign consent and follow all study visits and procedures
- Be 18–75 years old, and have unresectable or metastatic solid cancer confirmed as MSI-H or dMMR
- Your cancer must have grown or caused intolerable side effects after standard treatment
- Have at least one measurable tumor spot on scan (and it can’t be only from a prior radiotherapy target)
- Be able to provide recent tumor tissue and a blood sample for MSI/TMB/PD-L1 testing
- Overall health must be good enough (heart/lung/liver/kidney function acceptable) and you should not have major uncontrolled problems
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called HLX43 for people with advanced or metastatic solid tumors that have not responded to standard treatments. It aims to find safe dosing and understand how the drug works in the body.
This trial tests an investigational drug (HLX48) in people with advanced or metastatic solid tumors that have stopped responding to standard treatments. The goal is to see if it is safe and how well it works.
This trial tests a new experimental drug called HLX316 in people with advanced or metastatic (spread) solid cancers that have not responded to standard treatments. The drug is designed to help your immune system fight cancer cells.
This trial tests a new drug called HLX42 for people with advanced solid tumors (including a type of lung cancer called NSCLC) who have no good treatment options left. The goal is to see if it's safe and if it can help shrink tumors.
This early-phase study tests a new drug called HLX37 for people with advanced solid tumors that haven't responded to standard treatments. The goal is to see if it is safe and how it works in the body.
This trial tests a new drug, HLX3901, for people with advanced small cell lung cancer or neuroendocrine cancer that has worsened after previous treatments. The goal is to see if it's safe and how the body handles it.
Hear when a new MSI-H Solid Malignant Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.